Sg Americas Securities, LLC Tricida, Inc. Transaction History

Sg Americas Securities, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 02, 2023	BUY	$0.14 - $12.49 $25 - $2,285	183 Added 1.57%	11,821 $2,000
Q3 2022 Oct 31, 2022	SELL	$8.51 - $13.6 $2,765 - $4,420	-325 Reduced 2.72%	11,638 $122,000
Q2 2022 Jul 29, 2022	BUY	$7.31 - $11.85 $87,449 - $141,761	11,963 New	11,963 $116,000
Q1 2021 May 13, 2021	SELL	$4.52 - $7.8 $66,005 - $113,903	-14,603 Closed	0 $0
Q4 2020 Feb 04, 2021	SELL	$4.37 - $9.46 $43,665 - $94,524	-9,992 Reduced 40.63%	14,603 $103,000
Q3 2020 Nov 09, 2020	SELL	$8.56 - $26.93 $240,801 - $757,567	-28,131 Reduced 53.35%	24,595 $223,000
Q2 2020 Jul 20, 2020	BUY	$21.21 - $31.55 $896,970 - $1.33 Million	42,290 Added 405.23%	52,726 $1.45 Million
Q1 2020 Apr 30, 2020	BUY	$18.43 - $38.04 $41,043 - $84,715	2,227 Added 27.13%	10,436 $230,000
Q4 2019 Jan 28, 2020	BUY	$29.6 - $43.71 $242,986 - $358,815	8,209 New	8,209 $310,000
Q2 2019 Jul 29, 2019	SELL	$31.16 - $39.46 $115,073 - $145,725	-3,693 Closed	0 $0
Q1 2019 Apr 29, 2019	BUY	$19.96 - $38.62 $73,712 - $142,623	3,693 New	3,693 $143,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.